For many people, it’s unlikely that they will experience any significant respiratory health concerns throughout their lifetime, but looking after the health of our respiratory system is still important as we go through life. The healthier it is, the more we can do.
However, there are still millions of people in the UK who live daily with life-limiting inflammatory respiratory conditions such as Asthma and Chronic Obstructive Pulmonary Disorder (COPD). Figures suggest that around 5.4 million people in the UK have diagnosed Asthma*, and around 3 million have been diagnosed with COPD**.
COVID-19 has given rise to the chronic follow-up condition known as ‘long COVID’ which is much wider spread and can affect anyone after a COVID-19 infection. There have been around 23.9 million confirmed cases of COVID-19 in the UK***, with the Office for National Statistics reporting that around 2 million people have reported symptoms of long COVID.
In addition to the above, environmental pollutants can play a role in the health of our respiratory system. Global initiatives to reduce emissions will help this long-term, but it’s still something to be aware of, particularly if you live in busy, built-up city areas.
RESPIRO is a food supplement with a tri-active approach to helping ease the symptoms associated with inflammatory respiratory conditions, such as Asthma, COPD and long COVID, by utilising the following key ingredients:
• LithoLexal® – a unique marine plant-derived extract with anti-inflammatory properties. In studies, the LithoLexal® extract has demonstrated an ability to suppress the activity of the pro-inflammatory cytokines that are common in respiratory conditions such as Asthma, COPD and long COVID.
• LithoLexal®-MG – a form of highly bioavailable Magnesium, extracted from the same Icelandic mineral-rich seawater as LithoLexal®. Magnesium plays an important role in healthy lung function, helping with opening and relaxing the airways and helping to reduce inflammation.
• Vitamin D – a vital ingredient that works synergistically with Magnesium, and aids the bioavailability of key minerals absorbed into the body.
In 2022, we completed a trial with 50 UK residents who identified themselves as people living with Asthma and COPD to take part in a 3-month trial using LithoLexal® Respiro.
We asked the participants to fill out feedback surveys each month to help demonstrate the positive effect that Respiro was having across the course of the trial, and here are some of the results:
As you can see, the results were fantastic, helping to demonstrate that LithoLexal® Respiro can be effective in helping to alleviate the symptoms associated with inflammatory conditions such as Asthma and COPD.
Not only that, here’s what some of the participants of the trial had to say:
LithoLexal® Respiro is a daily food supplement, taken twice daily with water after food.
We recommend a minimum course of 3 months before you may be able to notice the benefits, but ongoing use after this is advised with regards to helping to alleviate symptoms over a longer period.
Purchase at the product page here: